Filtered By:
Condition: Headache
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Giant Cell Arteritis Presenting with Mania, Psychosis, and Cognitive Dysfunction: A Case Report
CONCLUSION: Corticosteroids led to a temporary exacerbation of manic symptoms, which improved after 3 to 4 weeks of continuous treatment, indicating that the symptoms were most likely associated with GCA. The patient manifested with clinical features and a clinical course that has, to our knowledge, not been described or published before. Therefore, GCA may be an underdiagnosed disease in psychiatric populations and should be considered in case of atypical, new-onset psychiatric disorders in the elderly.PMID:36819979 | PMC:PMC9938786 | DOI:10.1155/2023/7989712
Source: Case Reports in Psychiatry - February 23, 2023 Category: Psychiatry Authors: Heidi Madeleine Latvala Solveig Kl æbo Reitan Arne Einar Vaaler Source Type: research
A Case of Giant Cell Arteritis Presenting As Catastrophic Posterior Circulation Stroke: A Diagnostic Dilemma
We describe a case of a 75-year-old woman who presented with jaw claudication and temporal headache. A colour duplex ultrasonography and later biopsy of the temporal arteries confirmed GCA and she was commenced on oral steroids. She was subsequently readmitted with a new worsening vision of both eyes and confusion. Her brain images revealed acute bilateral vertebral artery thrombus with haemorrhagic transformation. She was loaded on intravenous steroids. The next day she developed vomiting, bilateral visual loss and a cardiac arrest from ventricular fibrillation. Following the return of spontaneous circulation, she was tak...
Source: Atherosclerosis - August 17, 2022 Category: Cardiology Authors: Joshua Wong Siang Chan Ashit Shetty Source Type: research
Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
CONCLUSION: The differential diagnosis remains difficult for suspected cases of LEV-induced MIL that could lead to delayed therapy initiation, and consequently incomplete recovery. Growing evidence suggests that a single administration of levamisole even in low doses might potentially lead to severe neurological deficit or death. Therefore, changes in medication management policies are required in order to prevent uncontrolled use of levamisole.PMID:34951579 | DOI:10.2174/1574886317666211224121517
Source: Current Drug Safety - December 24, 2021 Category: Drugs & Pharmacology Authors: Zakharova Maria Nikolaevna Zakroyshchikova Inessa Vladimirovna Kozlova Alexandra Olegovna Zabirova Alfiia Hodzhaevna Askarova Lola Shavkatovna Zhirova Ekaterina Stanislavovna Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
